Previous 10 | Next 10 |
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) declined again last week, falling from 3,323.71 points on Monday’s (July 29) open to 3,282.81 points as of 1:22 p.m. EDT on Friday (August 2). Over the course of the week, a number of top companies released pivotal Q2 2019 earnings, i...
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the closing of its previously announced underwritten public offering of 31,625,000 shares of its common stock to the public at $2.0...
Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of tradin...
Exicure ( OTCQB:XCUR ) has filed a prospectus to offer shares. More news on: Exicure, Inc., Healthcare stocks news, Read more ...
Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Exicure intends to gra...
Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced its appointment of Jeffrey L. Cleland, Ph.D. and Timothy P. Walbert to its Board of Directors. “We are excited to welcome...
Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and deve...
Conference call scheduled for 8:00 am ET on June 27, 2019 Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced data from a preclinical study evaluating the biodistribution of S...
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CFO, David Snyder, will give a company presentation on Tuesday, June 4th, 2019 at 3:40-4:00 pm MDT at the LD Micro 9th I...
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest meeting to accelerate oligonucleotide and...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 112.1% to $0.3033 on volume of 62,336,784 shares Warrantee Inc. (WRNT) rose 27.8% to $0.372 on volume of 55,635,565 shares Adial Pharmaceuticals Inc (ADIL) rose 110.3% to $2.2295 on volume of 54,549,4...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...